[Source: The American Journal of Pathology, full page: (LINK). Abstract, edited.]
Novel Avian-Origin Influenza A (H7N9) Virus Attaches to Epithelium in Both Upper and Lower Respiratory Tract of Humans
Debby van Riel, Lonneke M.E. Leijten, Miranda de Graaf, Jurre Y. Siegers, Kirsty R. Short, Monique I.J. Spronken, Eefje J.A. Schrauwen, Ron A.M. Fouchier, Albert D.M.E. Osterhaus, Thijs Kuiken
Address correspondence to Thijs Kuiken, D.V.M., Ph.D., Department of Viroscience, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Accepted 28 June 2013. published online 12 September 2013.
Abstract
Influenza A viruses from animal reservoirs have the capacity to adapt to humans and cause influenza pandemics. The occurrence of an influenza pandemic requires efficient virus transmission among humans, which is associated with virus attachment to the upper respiratory tract. Pandemic severity depends on virus ability to cause pneumonia, which is associated with virus attachment to the lower respiratory tract. Recently, a novel avian-origin H7N9 influenza A virus with unknown pandemic potential emerged in humans. We determined the pattern of attachment of two genetically engineered viruses containing the hemagglutinin of either influenza virus A/Shanghai/1/13 or A/Anhui/1/13 to formalin-fixed human respiratory tract tissues using histochemical analysis. Our results show that the emerging H7N9 virus attached moderately or abundantly to both upper and lower respiratory tract, a pattern not seen before for avian influenza A viruses. With the caveat that virus attachment is only the first step in the virus replication cycle, these results suggest that the emerging H7N9 virus has the potential both to transmit efficiently among humans and to cause severe pneumonia.
____
Supported by European Union FP7 ANTIGONE (contract number 278976), European Union FP7 FLUPIG (contract number 258084), NIAID-NIH (contract HHSN266200700010C), NHMRC C.J. Martin post-doctoral fellowship (1054081) (K.S.).
Disclosures: A.D.M.E.O. is partly employed by ViroClinics Biosciences B.V. and owns share certificates in ViroClinics Biosciences B.V. T.K. is a part-time consultant for ViroClinics Biosciences B.V.
PII: S0002-9440(13)00457-4
doi:10.1016/j.ajpath.2013.06.011
? 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
-
-------
Novel Avian-Origin Influenza A (H7N9) Virus Attaches to Epithelium in Both Upper and Lower Respiratory Tract of Humans
Debby van Riel, Lonneke M.E. Leijten, Miranda de Graaf, Jurre Y. Siegers, Kirsty R. Short, Monique I.J. Spronken, Eefje J.A. Schrauwen, Ron A.M. Fouchier, Albert D.M.E. Osterhaus, Thijs Kuiken
Address correspondence to Thijs Kuiken, D.V.M., Ph.D., Department of Viroscience, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Accepted 28 June 2013. published online 12 September 2013.
Abstract
Influenza A viruses from animal reservoirs have the capacity to adapt to humans and cause influenza pandemics. The occurrence of an influenza pandemic requires efficient virus transmission among humans, which is associated with virus attachment to the upper respiratory tract. Pandemic severity depends on virus ability to cause pneumonia, which is associated with virus attachment to the lower respiratory tract. Recently, a novel avian-origin H7N9 influenza A virus with unknown pandemic potential emerged in humans. We determined the pattern of attachment of two genetically engineered viruses containing the hemagglutinin of either influenza virus A/Shanghai/1/13 or A/Anhui/1/13 to formalin-fixed human respiratory tract tissues using histochemical analysis. Our results show that the emerging H7N9 virus attached moderately or abundantly to both upper and lower respiratory tract, a pattern not seen before for avian influenza A viruses. With the caveat that virus attachment is only the first step in the virus replication cycle, these results suggest that the emerging H7N9 virus has the potential both to transmit efficiently among humans and to cause severe pneumonia.
____
Supported by European Union FP7 ANTIGONE (contract number 278976), European Union FP7 FLUPIG (contract number 258084), NIAID-NIH (contract HHSN266200700010C), NHMRC C.J. Martin post-doctoral fellowship (1054081) (K.S.).
Disclosures: A.D.M.E.O. is partly employed by ViroClinics Biosciences B.V. and owns share certificates in ViroClinics Biosciences B.V. T.K. is a part-time consultant for ViroClinics Biosciences B.V.
PII: S0002-9440(13)00457-4
doi:10.1016/j.ajpath.2013.06.011
? 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
-
-------
Comment